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DEAR SIR,  
The article by Lim [1] on the development of 
oncology services in Malaysia was both insightful and 
comprehensive. It is interesting to read that cancer 
services are growing from strength to strength, with a 
national cancer institute planned. The field of oncology 
has been transformed over the last few decades with a 
proliferation in technological advances and a revolution 
occurring in molecular medicine. Interestingly, the 
thinking surrounding cancer service delivery has also 
been changing. Cancer care is increasingly being 
delivered within a multidisciplinary team environment, 
involving a host of highly skilled professionals. As 
oncologists, despite our unique skills in the diagnosis and 
treatment of cancer [2] we are, but a cog (albeit a 
necessary one), in a big wheel that is required to manage 
this complex disease. Therefore, it is arguable that 
oncology might actually be considered a multi-
disciplinary specialty. 
Every oncology department relies on a team of 
highly trained radiographers, physicists, pharmacists, 
nurses, and support staff for everyday functioning. With 
the resurgence of radiation research and development, 
intensity modulated and image guided radiotherapy [3] 
being prime examples, our reliance on our physicist and 
radiographer colleagues has never been greater. This 
includes all aspects of radiotherapy delivery, machine 
commissioning, quality assurance, treatment planning, 
and research. It has also been recognized that cancer 
centres benefit from taking an active role in public 
education and outreach, as this often leads to drastic 
improvements in patient satisfaction and overall 
perceptions. 
The concept of teamwork extends far beyond our 
own departments. One of our inseparable partners is 
radiology, which has evolved into a vast and 
multifaceted discipline. Different forms of imaging are 
used during a patient’s clinical course to diagnose, stage, 
plan, deliver intervention, and detect recurrence. 
Standard workhorses such as plain radiography and 
computed tomography (CT) are invaluable, but more 
specialized imaging is also important, including 
magnetic resonance imaging for detecting spinal cord 
lesions or imaging pelvic anatomy, bone scans for 
detecting skeletal metastases, and radiofrequency 
ablation for treating liver metastases. Even the most 
subtle of radiological features may predict a patient’s 
outcome, for example, the presence of rectal tumour 
found within 1 mm of the mesorectal fascia on a T2 
weighted MRI scan could signify a substantial increase 
in the chance of local recurrence and warrant aggressive 
downstaging by preoperative chemoradiotherapy [4]. 
An emergent technology is CT-positron emission 
tomography (CT-PET). It offers undeniably superior 
imaging quality and evidence of its efficacy is emerging 
for various tumour sites [5,6]. In addition, it is creating 
vast opportunities for in vivo imaging research, which is 
revolutionising the way drug trials are being designed 
(e.g., non-invasive pharmacokinetic and 
pharmacodynamic studies [7]) and the way molecular 
research is conducted. These benefits must be balanced 
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by the cost of providing this service. Not only does it 
incur an initial set-up cost of at least £4 million/MYR 
25.5 million (scanner and cyclotron) and annual running 
costs of at least £1.2 million/MYR 7.5 million [8], but 
requires the support of specialist radiopharmacists, 
physicists, and radiologists. Clearly, the best value for 
money would be for a multidisciplinary team to fully 
utilise this technology. 
Another specialty that we work closely with is 
pathology. Good pathological examination enables the 
right diagnosis to be made and, consequently, the right 
treatment to be delivered. This is especially critical when 
dealing with curable conditions. For each tumour type, 
different tumour characteristics can serve as either 
prognostic factors (to predict disease behaviour, e.g., 
recurrence rates, overall survival) or predictive factors 
(to predict tumour responses to anti-cancer therapy). For 
example, in breast cancer, the presence of lymph node 
involvement, lymphovascular space invasion, and a high 
tumour grade confers a poor prognosis, while hormone 
receptor or HER-2 receptor status would predict for a 
response to anti-oestrogen therapy or trastuzumab 
(Herceptin￿), respectively [9]. Such routine analysis 
often requires the support of highly specialised facilities 
and staff. Furthermore, new techniques are constantly 
being developed, eg., multi-gene and multi-protein 
analysis using gene-array and protein-array platforms 
[10], and this requires continued collaboration to 
evaluate and apply these technologies appropriately. 
Another key player in oncology is undoubtedly the 
surgeon. Modern surgical oncology practices, for 
example, total mesorectal resection in rectal cancer, 
maximal debulking in ovarian cancer, and nephrectomies 
in renal cancers have radically improved survival 
outcomes. The correct interplay between chemotherapy, 
radiotherapy, and surgery is critical, and one of the best 
ways of ensuring optimal sequencing and minimising 
delays is to build close working partnerships amongst 
professionals in these specialties. In the general care of 
the cancer patient, clinical oncologists often rely on input 
from their fellow specialists. This can be in the form of 
support of the critically ill patient (intensive 
care/anaesthetists), management of malignancy induced 
surgical complications, e.g., bowel perforation or 
obstruction (surgeons), or stabilisation of pathological 
fractures (orthopaedics), managing infectious or other 
medical complications (physicians), blood product 
support for patients undergoing chemotherapy (blood 
bank/haematologists), and pain management and end-of 
life care (palliative care/hospice). 
The final area that relies on collaborative effort is 
oncology research. Clinical trial units rely heavily on the 
support of research nurses, data managers, and 
statisticians. Translational research and drug 
development requires close cooperation between 
clinicians and scientists and, increasingly, from industry. 
Good research tends to flourish where a critical mass of 
people are able to generate ideas and lend expertise. 
Many cancer centres have realised this and have sought 
to provide closer interactions between specialties by 
developing joint clinics and multidisciplinary meetings 
and seminars. For the various specialties involved, a 
degree of sub-specialization is required to ensure 
familiarity with the specifics of oncological practice. 
This can sometimes require housing cancer treatment 
centres, research institutes, and regional teaching 
hospitals in close physical proximity to one another. 
National initiatives have also recognised the need for a 
multidisciplinary approach. Within the world-famous US 
National Cancer Institute (NCI), designated cancer 
centres are “encouraged to stimulate collaborative 
research involving more than one field of study” [11]. In 
a visionary move, the NCI has established the Cancer 
Biomedical Informatics Grid [12], which aims to enable 
global communication and resource sharing throughout it 
vast network of centres. The nascent UK equivalent, the 
National Cancer Research Institute (NCRI) Informatics 
Initiative, is similarly promoting the integration of basic 
science and clinical activity [13]. 
It is clear that a multidisciplinary approach in 
treating cancer patients facilitates improvements in 
patient care and outcomes. Therefore, it is vital that we 
continue to forge strong links with colleagues from all 
specialties, particularly when faced with increasing 
complexities in the treatment of this challenging disease. 
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